Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Coherus Oncology (CHRS) Short-term Investments (2017 - 2025)

Coherus Oncology's Short-term Investments history spans 8 years, with the latest figure at $83.2 million for Q4 2025.

  • For Q4 2025, Short-term Investments changed N/A year-over-year to $83.2 million; the TTM value through Dec 2025 reached $83.2 million, changed N/A, while the annual FY2025 figure was $83.2 million, N/A changed from the prior year.
  • Short-term Investments for Q4 2025 was $83.2 million at Coherus Oncology, down from $88.3 million in the prior quarter.
  • Across five years, Short-term Investments topped out at $140.0 million in Q1 2021 and bottomed at $14.9 million in Q4 2023.
  • The 4-year median for Short-term Investments is $88.3 million (2025), against an average of $85.7 million.
  • The largest annual shift saw Short-term Investments crashed 46.23% in 2021 before it tumbled 88.41% in 2023.
  • A 4-year view of Short-term Investments shows it stood at $108.2 million in 2021, then increased by 18.46% to $128.1 million in 2022, then crashed by 88.41% to $14.9 million in 2023, then soared by 460.32% to $83.2 million in 2025.
  • Per Business Quant, the three most recent readings for CHRS's Short-term Investments are $83.2 million (Q4 2025), $88.3 million (Q3 2025), and $20.7 million (Q2 2025).